BioRestorative Therapies (BRTX) Notes Payables (2010 - 2025)

BioRestorative Therapies (BRTX) has reported Notes Payables for 15 consecutive years, with $1.4 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Notes Payables fell 44.49% year-over-year to $1.4 million; the trailing twelve-month figure through Dec 2025 stood at $1.4 million (down 44.49% YoY), and the FY2025 full-year result was $1.4 million, down 44.49% from the prior year.
• Notes Payables fell to $1.4 million in Q4 2025 per BRTX's latest filing, from $2.0 million in the prior quarter.
• Across five years, Notes Payables topped out at $14.2 million in Q1 2022 and bottomed at $1.4 million in Q4 2025.
• Historically, Notes Payables has averaged $4.8 million across 4 years, with a median of $3.3 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Notes Payables sank 72.14% in 2023, then jumped 67.32% in 2024.
• Over 4 years, Notes Payables stood at $5.5 million in 2022, then tumbled by 72.14% to $1.5 million in 2023, then jumped by 63.27% to $2.5 million in 2024, then tumbled by 44.49% to $1.4 million in 2025.
• According to Business Quant data, Notes Payables over the past three periods registered $1.4 million, $2.0 million, and $2.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.